Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012

Uroplasty To Participate In Two Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2012/ .. cipate-in-two-upcoming-investor-conferences.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Uroplasty To Participate In Two Upcoming Investor Conferences -- MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ --

MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in two upcoming investor conferences in November – the Stephens Fall Investment Conference and the Lazard 9th Annual Healthcare Conference. Detailed information is provided below:

What:

Stephens Fall Investment Conference

Where:

New York Palace Hotel, New York, NY

Date:

Tuesday, November 13, 2012

Time:

4:00 pm ET



 

What:

Lazard 9th Annual Healthcare Conference

Where:

Pierre Hotel, New York, NY

Date:

Wednesday, November 14, 2012

Time:

11:00 am ET



David Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will discuss recent financial results and current corporate developments at both conferences.

Uroplasty will offer a live audio webcast of both events on the Company's website, [ www.uroplasty.com ], under Investor Information. An archived replay of the presentation will be available for 30 days, also at [ www.uroplasty.com ].

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors),

Medi Jiwani, Vice President, CFO, Treasurer

415.568.9349

952.426.6140

Chris Gale (Media), 646.201.5431

SOURCE Uroplasty, Inc.



RELATED LINKS
[ http://www.uroplasty.com ]

Publication Contributing Sources